Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced participation in the J.P. Morgan Global High Yield & Leveraged Finance Conference on March 1, 2022, at 9:15 a.m. ET. Key executives, including CFO Sam Eldessouky and SVP Arthur J. Shannon, will represent the company. Bausch Health focuses on improving health with a range of products in eye health, gastroenterology, and dermatology. The company's commitment to advancing global health and innovative solutions is highlighted.
Bausch Health reported its fourth-quarter and full-year 2021 financial results, revealing revenues of $2.196 billion for Q4 and $8.434 billion for the full year, up 5% from 2020. Despite a net income of $69 million in Q4, the company faced a full-year net loss of $948 million. Noteworthy achievements include the successful launch of four new products and progress in IPO preparations for Bausch + Lomb and Solta. However, cash generated from operations dropped significantly by 94% in Q4, emphasizing operational challenges.
Bausch Health Companies (NYSE/TSX: BHC) announced the U.S. launch of the OraFit™ custom clear aligner system on Feb. 22, 2022, aimed at correcting malocclusion. This system features a three-layer design with high-performance materials, providing a comfortable and aesthetically pleasing option for patients. With malocclusion affecting approximately 66% of individuals in the U.S., OraFit™ offers dentists a new solution that promotes patient acceptance and compliance. It also integrates a user-friendly online resource for dental professionals to streamline case submissions.
Bausch Health and its gastroenterology division, Salix Pharmaceuticals, have announced the opening of the 2022 Salix Gastrointestinal Health Scholars Program. This initiative will award scholarships of up to $10,000 to 10 students living with gastrointestinal diseases who are pursuing higher education. The application period runs until May 15, 2022, with recipient notifications expected in the summer. The program includes various awards categories, emphasizing the company’s commitment to supporting students.
KBRA has published its Fourth-Quarter 2021 U.S. Bank Compendium, offering insights into the U.S. banking sector's performance and credit metrics for the quarter. The report includes analyses of actions by larger banks regarding overdraft fees and features a quarterly ESG Bulletin. Notable highlights include summaries of publicly traded U.S. banks, key performance metrics, and data on top deposit franchises. Atlantic Union Bankshares Corporation (NASDAQ: AUB) is rated BBB+ with a positive outlook. For detailed insights, the full report is accessible online.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its subsidiary, Solta Medical Corporation, has filed a registration statement for a proposed IPO of its common shares. The share price and offering size are yet to be determined. Solta aims to list on the Nasdaq under the symbol 'SLTA'. Bausch Health has completed internal steps for launching both Solta and Bausch + Lomb IPOs, pending regulatory approvals. Major investment firms, including Goldman Sachs and Morgan Stanley, are managing the offering.
Bausch Health Companies (NYSE/TSX: BHC) will announce its financial results for Q4 and full-year 2021 on February 23, 2022. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Investors can access the call through the company’s Investor Relations website. Bausch Health focuses on improving lives through its health care products, primarily in eye health, gastroenterology, and dermatology.
Bausch + Lomb partners with Prevent Blindness for the seventh year during AMD Awareness Month, launching a campaign aimed at educating the public on Age-Related Macular Degeneration (AMD), which affects 16 million adults in the U.S. The initiative aims to raise awareness and funds, contributing $1 for each social media interaction, with a goal of $50,000. Bausch + Lomb's president emphasized the importance of eye examinations, as early diagnosis is crucial. The company also plans to release its Visionary Report to identify AMD education gaps.
Bausch Health Companies (BHC) has priced an offering of $1.0 billion in 6.125% senior secured notes due 2027. The proceeds will be utilized for refinancing efforts, encompassing existing loans and the redemption of senior notes due 2025. The refinancing will involve $2.5 billion in term loans and a $975 million revolving credit facility, contingent on the completion of the Bausch + Lomb IPO. The Notes are secured by existing assets and are offered under specific exemptions from registration laws.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched a $1.0 billion offering of new senior secured notes due 2027. The company also plans to refinance its existing credit agreement, which includes approximately $2.5 billion in new term B loans and a $975 million revolving credit facility. Proceeds will fund the redemption of outstanding 6.125% and 9.000% senior notes due 2025 and related expenses. The redemption is conditional upon completing the refinancing and receiving at least $7.0 billion from related transactions. The offering is not registered under U.S. securities laws.